Lv644
3078 积分 2024-09-24 加入
Discovery of noncovalent diaminopyrimidine-based Inhibitors for glioblastoma via a dual FAK/DNA targeting strategy
7天前
已完结
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
2个月前
已完结
2019 FDA drug approvals
2个月前
已完结
Discovery and Development of the Oral Complement Factor D Inhibitor Danicopan (ACH-4471)
2个月前
已完结
2018 FDA drug approvals
2个月前
已完结
2019 FDA drug approvals
2个月前
已完结
Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy
4个月前
已完结
An Overview of CDK Enzyme Inhibitors in Cancer Therapy
4个月前
已完结
Potential Target of CDK6 Signaling Pathway for Cancer Treatment
4个月前
已完结
An update on the development on tubulin inhibitors for the treatment of solid tumors
4个月前
已完结
皖公网安备34019202002308
